AR009985A1 - Aminotiofencarboxamidas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas - Google Patents
Aminotiofencarboxamidas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticasInfo
- Publication number
- AR009985A1 AR009985A1 ARP970104736A ARP970104736A AR009985A1 AR 009985 A1 AR009985 A1 AR 009985A1 AR P970104736 A ARP970104736 A AR P970104736A AR P970104736 A ARP970104736 A AR P970104736A AR 009985 A1 AR009985 A1 AR 009985A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical preparations
- procedure
- prepare
- hal
- aminotiofencarboxamidas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Aminotiofencarboxamidas de formula (I) en donde R1, R2 son independientemente H, A, OA, alquenilo, alquinilo, CF3 o Hal, siendo uno de losrestos R1 o R2 siempre H; R1 y R2 juntos, también son alquileno de 3 a 5 átomos de C. R3, R4 representan independientemente H, A, OA, NO2, NH2 o Hal, R3 Y R4juntos también son -O-CH2-CH2-, -O-CH2-O- o -O-CH2-CH2-O-; A, A son independientemente H o alquilo de 1 a 6 átomos de C. R5 es -X-Y; X es CO, CS oSO2. Y es un anillo isocíclicoo heterocíclico saturado o insaturado de 5 a 7 miembros que puede estar no sustituido o mono o disustituido con COOH,COOA,CONH2,CONAA,CONHA,CN,NHSO2A, N(SO2A)2 o SO2A. Hal es F,Cl,Br o I. Y n es 0, 1, 2 o 3, y a sus sales aceptables desde el puntode vista fisiologico. También serefiere a un procedimiento para preparar estos compuestos, al empleo de los mismos para preparar un medicamento, a las preparaciones farmacéuticas que loscontienen y a un procedimiento para obtener estas preparaciones farmacéuticas. Los compuestos de formula (I) y sus sales aceptables desde el punto de vistafisiologico actuan como inhibidores de la fofodiesterasa V y pueden ser empleados para el tratamiento de las enfermedades del sistemacardiocirculatorio y para la terapia delos trastornos de la potencia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19642451A DE19642451A1 (de) | 1996-10-15 | 1996-10-15 | Aminothiophencarbonsäureamide |
Publications (1)
Publication Number | Publication Date |
---|---|
AR009985A1 true AR009985A1 (es) | 2000-05-17 |
Family
ID=7808775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970104736A AR009985A1 (es) | 1996-10-15 | 1997-10-15 | Aminotiofencarboxamidas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas |
Country Status (26)
Country | Link |
---|---|
US (1) | US6143777A (es) |
EP (1) | EP0934301B1 (es) |
JP (1) | JP4243352B2 (es) |
KR (1) | KR100479811B1 (es) |
CN (1) | CN1110493C (es) |
AR (1) | AR009985A1 (es) |
AT (1) | ATE202347T1 (es) |
AU (1) | AU725741B2 (es) |
BR (1) | BR9712321A (es) |
CA (1) | CA2268886C (es) |
CZ (1) | CZ297253B6 (es) |
DE (2) | DE19642451A1 (es) |
DK (1) | DK0934301T3 (es) |
ES (1) | ES2159851T3 (es) |
GR (1) | GR3036341T3 (es) |
HK (1) | HK1020724A1 (es) |
HU (1) | HUP9904703A3 (es) |
NO (1) | NO991776L (es) |
PL (1) | PL192109B1 (es) |
PT (1) | PT934301E (es) |
RU (1) | RU2184731C2 (es) |
SI (1) | SI0934301T1 (es) |
SK (1) | SK283807B6 (es) |
TW (1) | TW438791B (es) |
WO (1) | WO1998016521A1 (es) |
ZA (1) | ZA979199B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6727258B2 (en) * | 1997-10-29 | 2004-04-27 | King Pharmaceutical Research & Development, Inc. | Allosteric adenosine receptor modulators |
US6410584B1 (en) | 1998-01-14 | 2002-06-25 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells with indole derivatives |
JP2002518471A (ja) * | 1998-06-19 | 2002-06-25 | ノバルティス アクチエンゲゼルシャフト | ピリミジノン誘導体の製法 |
US6200771B1 (en) | 1998-10-15 | 2001-03-13 | Cell Pathways, Inc. | Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia |
US6133271A (en) * | 1998-11-19 | 2000-10-17 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives |
US6187779B1 (en) | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
US6369092B1 (en) | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
US6034099A (en) * | 1998-11-24 | 2000-03-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones |
US6077842A (en) * | 1998-11-24 | 2000-06-20 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives |
US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
US6020379A (en) * | 1999-02-19 | 2000-02-01 | Cell Pathways, Inc. | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia |
US6479493B1 (en) | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
ATE404550T1 (de) * | 2001-09-21 | 2008-08-15 | Smithkline Beecham Corp | Chemische verbindungen |
ES2315430T3 (es) * | 2001-10-04 | 2009-04-01 | Smithkline Beecham Corporation | Inhibidores de nf-kb. |
US7208516B2 (en) | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7276529B2 (en) | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
CN1308323C (zh) * | 2002-07-24 | 2007-04-04 | 三井化学株式会社 | 2-烷基-3-氨基噻吩衍生物的制造方法 |
US7179836B2 (en) * | 2002-09-20 | 2007-02-20 | Smithkline Beecham Corporation | Chemical compounds |
FR2875807B1 (fr) * | 2004-09-30 | 2006-11-17 | Servier Lab | Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
JP2009513672A (ja) | 2005-10-31 | 2009-04-02 | ブレインセルス,インコーポレイティド | 神経発生のgaba受容体媒介調節 |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
CA2651862A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
AU2007292848A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
RU2472791C2 (ru) * | 2008-08-27 | 2013-01-20 | КалсиМедика Инк. | Соединения, модулирующие внутриклеточный кальций |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
RU2503671C1 (ru) * | 2012-07-31 | 2014-01-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" | (Z)-2-[(3-КАРБАМОИЛ-4,5,6,7-ТЕТРАГИДРОБЕНЗО[b]ТИЕН-2-ИЛ)АМИНО]-4-(4-R-ФЕНИЛ)-4-ОКСОБУТ-2-ЕНОВЫЕ КИСЛОТЫ, ОБЛАДАЮЩИЕ АНАЛЬГЕТИЧЕСКОЙ АКТИВНОСТЬЮ |
RU2501795C1 (ru) * | 2012-10-01 | 2013-12-20 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" | N-R-АМИДЫ (Z)-2[(3-ЭТОКСИКАРБОНИЛ)-4,5,6,7-ТЕТРАГИДРОБЕНЗО[b]ТИЕН-2-ИЛ)АМИНО]-4-ФЕНИЛ-4-ОКСОБУТ-2-ЕНОВЫХ КИСЛОТ, ОБЛАДАЮЩИЕ АНАЛЬГЕТИЧЕСКОЙ АКТИВНОСТЬЮ |
US10300042B2 (en) | 2014-06-23 | 2019-05-28 | Celgene Corporation | Apremilast for the treatment of a liver disease or a liver function abnormality |
RU2722176C1 (ru) * | 2019-09-06 | 2020-05-28 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" | (z)-2((4-r1-5-r2-3-(этоксикарбонил)тиофен-2-ил)амино)-4-оксо-4-r3-бут-2-еновые кислоты, обладающие противомикробной активностью |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5075310A (en) * | 1988-07-01 | 1991-12-24 | Smith Kline & French Laboratories, Ltd. | Pyrimidone derivatives as bronchodilators |
US5753692A (en) * | 1992-02-19 | 1998-05-19 | Industrial Technology Research Institute | Medicinal thiophene compounds |
US5356926A (en) * | 1992-02-24 | 1994-10-18 | Warner-Lambert Company | 3-alkyloxy-, aryloxy-, or arylalkyloxy-benzo [β]thiophene-2-carboxamides as inhibitors of cell adhesion |
DE4230755A1 (de) * | 1992-09-14 | 1994-03-17 | Schering Ag | Verwendung von PDE-Inhibitoren bei der Behandlung von Nieren- und Ureter-Erkrankungen |
DK148292D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Forbindelser |
GB9309324D0 (en) * | 1993-05-06 | 1993-06-16 | Bayer Ag | Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives |
DE4317076A1 (de) * | 1993-05-21 | 1994-11-24 | Bayer Ag | Benzthiophencarbonsäureamid-S-oxide |
DE69507197T2 (de) * | 1994-05-31 | 1999-05-27 | Bayer Ag, 51373 Leverkusen | Aminobenzofuryl- und -thienylderivate |
US5863936A (en) * | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
CA2268164A1 (en) * | 1996-10-08 | 1998-04-16 | Yao-Chang Xu | New serotonin 5-ht1f agonists |
US5783597A (en) * | 1997-03-04 | 1998-07-21 | Ortho Pharmaceutical Corporation | 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use |
-
1996
- 1996-10-15 DE DE19642451A patent/DE19642451A1/de not_active Withdrawn
-
1997
- 1997-10-06 TW TW086114589A patent/TW438791B/zh active
- 1997-10-08 RU RU99109576/04A patent/RU2184731C2/ru not_active IP Right Cessation
- 1997-10-08 WO PCT/EP1997/005531 patent/WO1998016521A1/de active IP Right Grant
- 1997-10-08 SI SI9730192T patent/SI0934301T1/xx unknown
- 1997-10-08 PT PT97912140T patent/PT934301E/pt unknown
- 1997-10-08 CN CN97198839A patent/CN1110493C/zh not_active Expired - Fee Related
- 1997-10-08 JP JP51798698A patent/JP4243352B2/ja not_active Expired - Fee Related
- 1997-10-08 CZ CZ0124099A patent/CZ297253B6/cs not_active IP Right Cessation
- 1997-10-08 PL PL332802A patent/PL192109B1/pl unknown
- 1997-10-08 EP EP97912140A patent/EP0934301B1/de not_active Expired - Lifetime
- 1997-10-08 ES ES97912140T patent/ES2159851T3/es not_active Expired - Lifetime
- 1997-10-08 AT AT97912140T patent/ATE202347T1/de not_active IP Right Cessation
- 1997-10-08 SK SK432-99A patent/SK283807B6/sk unknown
- 1997-10-08 US US09/284,501 patent/US6143777A/en not_active Expired - Fee Related
- 1997-10-08 AU AU49451/97A patent/AU725741B2/en not_active Ceased
- 1997-10-08 BR BR9712321-8A patent/BR9712321A/pt not_active Application Discontinuation
- 1997-10-08 HU HU9904703A patent/HUP9904703A3/hu unknown
- 1997-10-08 CA CA002268886A patent/CA2268886C/en not_active Expired - Fee Related
- 1997-10-08 DK DK97912140T patent/DK0934301T3/da active
- 1997-10-08 DE DE59703869T patent/DE59703869D1/de not_active Expired - Lifetime
- 1997-10-08 KR KR10-1999-7003246A patent/KR100479811B1/ko not_active IP Right Cessation
- 1997-10-14 ZA ZA9709199A patent/ZA979199B/xx unknown
- 1997-10-15 AR ARP970104736A patent/AR009985A1/es not_active Application Discontinuation
-
1999
- 1999-04-14 NO NO991776A patent/NO991776L/no not_active Application Discontinuation
- 1999-11-04 HK HK99105058A patent/HK1020724A1/xx not_active IP Right Cessation
-
2001
- 2001-08-07 GR GR20010401193T patent/GR3036341T3/el not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR009985A1 (es) | Aminotiofencarboxamidas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas | |
AR008504A1 (es) | Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas | |
AR009052A1 (es) | Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen y un procedimiento para obtener estas preparaciones farmaceuticas | |
AR010962A1 (es) | Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas. | |
HUP0100815A2 (hu) | Neurológiai és neuropszichiátriai rendellenességek kezelésére szolgáló gyógyszerkészítmények | |
AR016762A1 (es) | Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo | |
YU88491A (sh) | Amidi izoksazol-4-karboksilne kiseline i amidi hidroksialkiliden-cijanosirćetne kiseline i postupak za dobijanje farmaceutskih preparata koji sadrže ta jedinjenja | |
AR028988A1 (es) | Derivados amida, proceso para su preparacion, composicion farmaceutica que los comprende, y su uso en la fabricacion de un medicamento util en el tratamiento de enfermedades o afecciones clinicas mediadas por citoquinas | |
PA8432901A1 (es) | Compuestos de piridilpirrol | |
FI946073A0 (fi) | Vitamiini D-sarjan, 20-asemassa modifioituja johdannaisia, menetelmä tällaisten johdannaisten valmistamiseksi, menetelmässä käytettäviä välituotteita, mainittuja johdannaisia sisältäviä farmaseuttisia valmisteita ja johdannaisten käyttö lääkeaineiden valmistamiseen | |
DK0513702T3 (da) | Melatoninderivater til anvendelse til behandling af søvnlidelser og til præ-anæstetisk medicinering | |
ES2054860T3 (es) | Nuevos derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion, asi como a su utilizacion como medicamentos. | |
GB1069343A (en) | Propanolamine derivatives | |
AR024819A1 (es) | Derivados de la n-(indolcarbonil)-piperazina, un procedimiento para su preparacion, su empleo para preparar un medicamento, los medicamentos a base de los mismos y las preparaciones farmaceuticas que los contienen. | |
ES2077199T3 (es) | Nuevas piperacinas 1,4-disustituidas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
ES2052028T3 (es) | Un metodo para preparar compuestos diarilicos anti-ateroscleroticos. | |
ES2041705T3 (es) | Procedimiento para la preparacion de 1-(4-hidroxi-3,5-di-terc-butil-benzoil)-homopiperazina y sus derivados. | |
MX9304467A (es) | Nuevos derivados fosfonados de ariletanolaminas, procedimiento para su preparacion y composiciones farmaceuticas y veterinarias que los contienen. | |
FR2457689A1 (fr) | Medicament hypolipemique a base de carnitine | |
AR001769A1 (es) | Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación | |
AR024818A1 (es) | Derivados de la n-(indolcarbonil)-piperazina, un procedimiento para su preparacion, su empleo para preparar un medicamento, los medicamentos a base de losmismos y las preparaciones farmaceuticas que los contienen. | |
DE3786256D1 (de) | Antifolat-mittel. | |
ES2041815T3 (es) | Un procedimiento para la obtencion de derivados de ornitina 5-sustituidos. | |
MX9303574A (es) | Compuestos heterociclicos que son inhibidores de la enzima aromatasa, proceso para su preparacion ycomposiciones farmaceuticas que los contienen. | |
HUP0203118A2 (hu) | Béta-diszubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |